Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The American Society of Hematology (ASH) and the European Hematology Association (EHA) have announced the names of 20 early-career hematologists who will participate in the joint 2017 Translational Research Training in Hematology (TRTH) program. These include Dr Alice Giustacchini (WIMM-NDCLS, Mead/Jacobsen Group) and Dr Lynn Quek (WIMM-NDCLS, Vyas Group). Congratulations to Alice and Lynn for being invited to take part in this prestigious scheme.

Red blood cells

TRTH is a rigorous year-long training and mentoring experience that helps junior scientists build successful careers in translational hematologic research. Under the guidance of international leaders, participants learn the fundamental principles related to translational research, including developing a hypothesis and testing that hypothesis in the laboratory by applying the scientific method. TRTH participants include medical, biomedical, and pharmaceutical trainees who are actively employed in a hematology-related research environment as fellows or junior faculty who have completed their fellowship training within the past three years. 

This year’s TRTH program will begin with a week-long course March 11-17 in Italy. It is designed to give participants a more profound understanding of translational research methodology and career development. The course includes didactic and interactive sessions and one-on-one faculty mentoring that focuses on refining participants’ research proposals. TRTH participants will convene again at the 2017 EHA Annual Congress, June 22-25 in Madrid, where they will attend small group mentoring sessions. Finally, participants will present the status of their projects at the conclusion of the program at the 2017 ASH Annual Meeting, December 9-12 in Atlanta.

The TRTH program is made possible by generous support from Celgene, Takeda Oncology, Janssen Pharmaceutica NV, AMGEN (EUROPE) GmbH, Bristol-Myers Squibb, Incyte Corporation, Gilead Sciences, Inc., Astellas Pharma, AstraZeneca, F. Hoffmann-La Roche Ltd.

“I’m pleased that ASH and EHA continue to offer this unique opportunity for junior scientists to learn the principles of translational research. This experience will give them the knowledge and support to turn their talents into discoveries that will count for patients,” said ASH President Kenneth C. Anderson, MD, of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute in Boston. “As a mentor myself, I am proud that ASH supports programs that train and support the next generation of scientists.”

 

See the joint 2017 Translational Research Training in Hematology (TRTH) program.